Cardiovascular drugs market to be valued at $247.8b by 2033

Better patient awareness and personalised therapies are driving growth.

The global cardiovascular drugs market is expected to reach $247.8b by 2033 at a compound annual growth rate of 4%, according to DataM Intelligence.

The sector’s expansion is attributed to the rising prevalence of cardiovascular diseases linked to ageing populations and changing lifestyles, such as unhealthy diets and reduced physical activity.

“This market is undergoing significant transformation driven by advances in drug development and the integration of tech-enabled care solutions,” the report said.

In addition, better patient awareness and adoption of personalised therapies are driving market growth.

By disease indication type, the hypertension segment is expected to record the highest growth rate during the forecast period.

“Increased diagnosis and awareness have led to greater use of antihypertensive drugs, fueling steady market expansion,” it added.